

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI787450

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name			Execution Date
PNC Bank, National Association			12/30/2024
RECEIVING PARTY DATA			
Company Name:	Nephron Pharmaceuticals Corporation		
Street Address:	4500 12th Street Extension		
City:	West Columbia		
State/Country:	SOUTH CAROLINA		
Postal Code:	29172		
PROPERTY NUMBERS Total: 8			
Property Type	Number		
Patent Number:	D565193		
Patent Number:	11344562		
Patent Number:	D731642		
Application Number:	16172434		
Application Number:	18350385		
Application Number:	17826602		
Application Number:	17441952		
Application Number:	17771519		
CORRESPONDENCE DATA			
Fax Number:	6175236850		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6175232700		
Email:	susan.dinicola@hklaw.com,hunter.hullett@hklaw.com		
Correspondent Name:	Susan C. DiNicola		
Address Line 1:	Holland & Knight LLP		
Address Line 2:	10 St. James Avenue		
Address Line 4:	Boston , MASSACHUSETTS 02116		
ATTORNEY DOCKET NUMBER:	171631.00013		
NAME OF SUBMITTER:	Susan DiNicola		
SIGNATURE:	/Susan DiNicola/		

PATENT

DATE SIGNED:	01/28/2025
Total Attachments: 3 source=Payoff - Termination and Release of Second AR Assignment for Security (Patents) (PNC-Nephron) - Executed#page1.tiff source=Payoff - Termination and Release of Second AR Assignment for Security (Patents) (PNC-Nephron) - Executed#page2.tiff source=Payoff - Termination and Release of Second AR Assignment for Security (Patents) (PNC-Nephron) - Executed#page3.tiff	

**TERMINATION AND RELEASE OF SECOND AMENDED AND RESTATED
ASSIGNMENT FOR SECURITY (PATENTS)**

THIS TERMINATION AND RELEASE OF SECOND AMENDED AND RESTATED ASSIGNMENT FOR SECURITY (PATENTS) (this "Termination"), is dated as of December 30, 2024, and made by **PNC BANK, NATIONAL ASSOCIATION** (the "Grantee"), to **NEPHRON PHARMACEUTICALS CORPORATION**, a Florida corporation (the "Grantor").

WHEREAS, pursuant to that certain Second Amended and Restated Assignment for Security (Patents) dated as of September 11, 2023, made by Grantor in favor of Grantee (the "Security Agreement"), a security interest was granted by the Grantor to Grantee in certain collateral, including the Intellectual Property (as hereinafter defined);

WHEREAS, the Security Agreement was recorded with the patent division of the United States Patent and Trademark Office on September 11, 2023, at Reel/Frame 064861/0641;

WHEREAS, Grantee now desires to terminate the Security Agreement and terminate, release and discharge its security interest in the Intellectual Property;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and upon the terms set forth in this Termination, Grantee hereby states as follows:

1. Definitions. The term "Intellectual Property," as used herein, shall mean all of the Grantor's right, title and interest of every kind and nature as of the date hereof in the Intellectual Property listed on Exhibit A hereto.

2. Release of Security Interest. Grantee hereby terminates the Security Agreement and terminates, releases and discharges its security interest in the Intellectual Property and reassigns to the person or persons legally entitled thereto all right, title and interest of Grantee in the Intellectual Property.

[remainder of page intentionally blank]

IN WITNESS WHEREOF, the Grantee has caused this Termination to be executed by its duly authorized officer as of the date first written above.

PNC BANK, NATIONAL ASSOCIATION

By:  _____

Name: Kevin Trout

Title: Vice President

Exhibit A

Patent	Name of Owner	Status and Jurisdiction/Office Where Registered	Publication/Application Number	Registration Number
Unit Dose Vial	Nephron Pharmaceuticals Corporation	GRANTED (USPTO)	Application No. 29/249,407	D565193 (3/25/2008)
Aqueous Nebulization Composition	Nephron Pharmaceuticals Corporation	GRANTED (USPTO)	Application No. 16/103,630	11,344,562 (5/31/2022)
Tiotropium Inhalation Solution for Nebulization	Nephron Pharmaceuticals Corporation	PENDING (USPTO)	Application No. 16/172,434	n/a
Tiotropium Inhalation Solution for Nebulization	Nephron Pharmaceuticals Corporation	PENDING (USPTO)	Application No. 18/350,385	n/a
Container for Liquid	Nephron Pharmaceuticals Corporation	GRANTED (USPTO)	Application No. 29/420,647	D731642 (6/9/2015)
Aqueous Nebulization Composition	Nephron Pharmaceuticals Corporation	PENDING (USPTO)	Application No. 17/826,602	n/a
Blockchain Systems and Methods for Remote Monitoring	Nephron Pharmaceuticals Corporation	PENDING (USPTO)	Application No. 17/441,952	n/a
Automatic Syringe Handling System	Nephron Pharmaceuticals Corporation	PENDING (USPTO)	Application No. 17/771,519	n/a

PATENT

REEL: 070036 FRAME: 0792

RECORDED: 01/28/2025